Research Papers

@article{Rizza2010,
title = {Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based Hepatitis C virus therapy in HIV/Hepatitis C virus-coinfected individuals},
author = {Stacey A. Rizza and Nathan W. Cummins and David N. Rider and Sahar Saeed and Marina B. Klein and Andrew D. Badley},
url = {https://www.ncbi.nlm.nih.gov/pubmed/20802294},
doi = {10.1097/QAD.0b013e32833eacfd},
year = {2010},
date = {2010-11-15},
journal = {AIDS},
volume = {24},
number = {17},
pages = {2639-2644},
abstract = {OBJECTIVE(S):
HIV/hepatitis C virus (HCV) coinfection causes accelerated liver disease compared to HCV monoinfection, and only 30-60% of HIV/HCV-coinfected individuals respond to HCV therapy with pegylated interferon and ribavirin. There are currently no biomarkers that predict treatment response in these coinfected patients.
DESIGN:
We investigated whether there is an association between HCV treatment response and SNPs of apoptosis-related genes during HIV/HCV coinfection.
METHOD:
Genomic DNA from 53 HIV/HCV-coinfected individuals was analyzed for 82 SNPs of 10 apoptosis-related genes.
RESULTS:
We found that the presence of the rs4242392 SNP in tumor necrosis factor receptor superfamily, member 10a (TNFRSF10A), which encodes for tumor necrosis factor-related apoptosis-inducing ligand receptor 1, predicts poor outcome to HCV therapy, in HIV/HCV-co-infected patients [odds ratio 5.91 (95% confidence interval 1.63-21.38, P = 0.007)].
CONCLUSION:
The rs4242392 SNP of the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 gene predicted poor interferon-based HCV treatment response in HIV/HCV-coinfected patients.},
keywords = {Apoptosis-inducing ligand receptor 1, HIV-HCV co-infection, Polymorphism, Tumor necrosis},
pubstate = {published},
tppubtype = {article}
}